Intrexon Corporation Company Profile (NYSE:XON)

About Intrexon Corporation (NYSE:XON)

Intrexon Corporation logoIntrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company's domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company's synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company's technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NYSE:XON
  • CUSIP: N/A
  • Web:
  • Market Cap: $2.2 billion
  • Outstanding Shares: 120,519,000
Average Prices:
  • 50 Day Moving Avg: $19.19
  • 200 Day Moving Avg: $21.07
  • 52 Week Range: $17.03 - $32.90
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -26.06
  • P/E Growth: 0.4500
Sales & Book Value:
  • Annual Revenue: $202.92 million
  • Price / Sales: 10.83
  • Book Value: $4.57 per share
  • Price / Book: 3.99
  • EBITDA: ($99,620,000.00)
  • Net Margins: -60.63%
  • Return on Equity: -19.08%
  • Return on Assets: -11.53%
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 2.45%
  • Quick Ratio: 2.25%
  • Average Volume: 884,181 shs.
  • Beta: 1.48
  • Short Ratio: 32.63

Frequently Asked Questions for Intrexon Corporation (NYSE:XON)

What is Intrexon Corporation's stock symbol?

Intrexon Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "XON."

How were Intrexon Corporation's earnings last quarter?

Intrexon Corporation (NYSE:XON) announced its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.05. The business earned $54.40 million during the quarter, compared to analysts' expectations of $57.17 million. Intrexon Corporation had a negative return on equity of 19.08% and a negative net margin of 60.63%. The business's revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter last year, the business posted ($0.42) earnings per share. View Intrexon Corporation's Earnings History.

When will Intrexon Corporation make its next earnings announcement?

Intrexon Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Intrexon Corporation.

Where is Intrexon Corporation's stock going? Where will Intrexon Corporation's stock price be in 2017?

6 equities research analysts have issued 1 year price objectives for Intrexon Corporation's shares. Their forecasts range from $27.00 to $57.00. On average, they expect Intrexon Corporation's share price to reach $43.20 in the next twelve months. View Analyst Ratings for Intrexon Corporation.

Who are some of Intrexon Corporation's key competitors?

Who are Intrexon Corporation's key executives?

Intrexon Corporation's management team includes the folowing people:

  • Randal J. Kirk, Chairman of the Board, Chief Executive Officer
  • Thomas D. Reed Ph.D., Founder, Chief Science Officer
  • Rick L. Sterling CPA, Chief Financial Officer
  • Andrew J. Last Ph.D., Chief Operating Officer
  • Joel Liffmann, Senior Vice President - Finance
  • Jack Anthony Bobo, Senior Vice President, Chief Communications Officer
  • Ena Chan Cratsenburg, Senior Vice President - Consumer Sector
  • Nir Nimrodi, Senior Vice President - Corporate Development
  • Jeffrey T. Perez, Senior Vice President — Intellectual Property Affairs
  • Christopher Basta, Vice President - Investor Relations

Who owns Intrexon Corporation stock?

Intrexon Corporation's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include KIRK RANDAL J (46.70%). Company insiders that own Intrexon Corporation stock include Andrew J Last, Dean J Mitchell, Donald P Lehr, Fred Hassan, Jeffrey Thomas Perez, Joel D Liffman, Nir Nimrodi, Randal J Kirk, Robert B Shapiro and Suma Krishnan. View Institutional Ownership Trends for Intrexon Corporation.

How do I buy Intrexon Corporation stock?

Shares of Intrexon Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intrexon Corporation's stock price today?

One share of Intrexon Corporation stock can currently be purchased for approximately $18.24.

MarketBeat Community Rating for Intrexon Corporation (NYSE XON)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  189 (Vote Outperform)
Underperform Votes:  121 (Vote Underperform)
Total Votes:  310
MarketBeat's community ratings are surveys of what our community members think about Intrexon Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Intrexon Corporation (NYSE:XON) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $43.20 (136.84% upside)
Consensus Price Target History for Intrexon Corporation (NYSE:XON)
Price Target History for Intrexon Corporation (NYSE:XON)
Analysts' Ratings History for Intrexon Corporation (NYSE:XON)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/6/2017Northland SecuritiesReiterated RatingBuy$27.00N/AView Rating Details
10/6/2017Griffin SecuritiesReiterated RatingBuy$55.00N/AView Rating Details
10/5/2017JMP SecuritiesReiterated RatingOutperform$42.00N/AView Rating Details
4/4/2017Stifel NicolausReiterated RatingBuy$57.00HighView Rating Details
3/14/2017WunderlichLower Price TargetBuy$50.00 -> $35.00HighView Rating Details
11/11/2016J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
3/3/2016Bank of America CorporationReiterated RatingNeutral$41.00 -> $38.00N/AView Rating Details
3/1/2016MizuhoReiterated RatingNeutral$28.00 -> $29.00N/AView Rating Details
(Data available from 10/19/2015 forward)


Earnings History for Intrexon Corporation (NYSE:XON)
Earnings by Quarter for Intrexon Corporation (NYSE:XON)
Earnings History by Quarter for Intrexon Corporation (NYSE XON)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.23)N/AView Earnings Details
8/9/2017Q2 2017($0.21)($0.16)$57.17 million$54.40 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.22)($0.26)$49.08 million$53.70 millionViewN/AView Earnings Details
3/1/2017Q416($0.23)($0.37)$52.53 million$46.00 millionViewListenView Earnings Details
11/9/2016Q316($0.21)($0.24)$51.70 million$48.99 millionViewListenView Earnings Details
8/9/2016Q216($0.26)($0.42)$53.78 million$52.50 millionViewN/AView Earnings Details
5/10/2016Q1($0.20)($0.55)$46.26 million$43.40 millionViewListenView Earnings Details
2/29/2016Q415($0.18)($0.28)$41.82 million$41.50 millionViewListenView Earnings Details
11/9/2015Q3($0.21)($0.34)$40.84 million$53.40 millionViewN/AView Earnings Details
8/10/2015Q215($0.04)$0.01$55.93 million$44.90 millionViewListenView Earnings Details
5/11/2015Q115($0.12)$0.25$32.90 million$33.80 millionViewListenView Earnings Details
3/2/2015Q414($0.16)$0.18$26.11 million$31.10 millionViewN/AView Earnings Details
11/13/2014Q314($0.16)($0.53)$19.40 million$21.20 millionViewN/AView Earnings Details
8/14/2014Q214($0.13)($0.11)$9.39 million$11.80 millionViewN/AView Earnings Details
5/7/2014Q1$0.06$0.04$11.25 million$7.90 millionViewN/AView Earnings Details
3/31/2014Q413($0.14)($0.13)$8.38 million$7.10 millionViewN/AView Earnings Details
11/7/2013($0.03)$0.15$9.79 million$6.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Intrexon Corporation (NYSE:XON)
2017 EPS Consensus Estimate: ($0.85)
2018 EPS Consensus Estimate: ($0.75)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.22)($0.22)($0.22)
Q2 20171($0.19)($0.19)($0.19)
Q3 20171($0.23)($0.23)($0.23)
Q4 20171($0.21)($0.21)($0.21)
Q1 20181($0.21)($0.21)($0.21)
Q2 20181($0.19)($0.19)($0.19)
Q3 20181($0.18)($0.18)($0.18)
Q4 20181($0.17)($0.17)($0.17)
(Data provided by Zacks Investment Research)


Dividend History for Intrexon Corporation (NYSE:XON)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Intrexon Corporation (NYSE:XON)
Insider Ownership Percentage: 56.30%
Institutional Ownership Percentage: 82.11%
Insider Trades by Quarter for Intrexon Corporation (NYSE:XON)
Institutional Ownership by Quarter for Intrexon Corporation (NYSE:XON)
Insider Trades by Quarter for Intrexon Corporation (NYSE:XON)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/22/2017Robert B ShapiroDirectorBuy2,850$17.50$49,875.00View SEC Filing  
8/14/2017Andrew J LastCOOBuy2,000$19.99$39,980.00View SEC Filing  
8/11/2017Dean J MitchellDirectorBuy5,000$18.33$91,650.00View SEC Filing  
8/11/2017Donald P LehrInsiderBuy1,094$18.33$20,053.02View SEC Filing  
8/11/2017Jeffrey Thomas PerezSVPBuy1,000$17.89$17,890.00View SEC Filing  
8/11/2017Randal J KirkCEOBuy132,625$18.85$2,499,981.25View SEC Filing  
12/13/2016Randal J KirkCEOBuy34,606$28.90$1,000,113.40View SEC Filing  
12/12/2016Joel D LiffmanSVPBuy8,500$28.62$243,270.00View SEC Filing  
12/1/2016Fred HassanDirectorBuy6,900$29.02$200,238.00View SEC Filing  
8/29/2016Nir NimrodiSVPBuy4,000$26.12$104,480.00View SEC Filing  
5/13/2016Randal J KirkCEOBuy41,830$23.92$1,000,573.60View SEC Filing  
12/11/2015Randal J KirkCEOBuy124,475$29.85$3,715,578.75View SEC Filing  
12/7/2015Randal J KirkCEOBuy237,525$30.69$7,289,642.25View SEC Filing  
12/4/2015Suma KrishnanSVPSell20,900$35.66$745,294.00View SEC Filing  
1/27/2015Randal J KirkCEOBuy555,556$27.00$15,000,012.00View SEC Filing  
5/13/2014Donald LehrInsiderBuy1,850$15.99$29,581.50View SEC Filing  
5/13/2014Randal KirkCEOBuy65,173$15.19$989,977.87View SEC Filing  
5/9/2014Kelly HuangSVPBuy3,200$15.78$50,496.00View SEC Filing  
5/9/2014Krish KrishnanCOOBuy20,900$14.21$296,989.00View SEC Filing  
3/27/2014Randal KirkCEOBuy243,001$25.72$6,249,985.72View SEC Filing  
3/4/2014Gregory Ian FrostSVPBuy100,000$25.95$2,595,000.00View SEC Filing  
8/13/2013Jeffrey B KindlerDirectorBuy33,000$16.00$528,000.00View SEC Filing  
8/13/2013Randal J KirkCEOBuy1,887,500$16.00$30,200,000.00View SEC Filing  
8/13/2013Thomas D ReedInsiderBuy1,800$16.00$28,800.00View SEC Filing  
8/13/2013Thomas R KasserSVPBuy5,000$16.00$80,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Intrexon Corporation (NYSE:XON)
Latest Headlines for Intrexon Corporation (NYSE:XON)
DateHeadline logoIntrexon inks $100M funding deal with billionaire founder Randal Kirk - October 18 at 10:52 AM logoIntrexon Corporation Enters into $100 Million Preferred Stock Equity Facility - PR Newswire (press release) - October 17 at 9:28 AM logoIntrexon Corporation Enters into $100 Million Preferred Stock Equity Facility - October 17 at 9:27 AM logoIntrexon Corporation (XON) Cut to Sell at Zacks Investment Research - October 16 at 2:56 PM logoZIOPHARM Oncology Announces First Patient Dosed in New Phase 1 Study of Ad-RTS-hIL-12 plus Veledimex for the Treatment of Pediatric Brain Tumors - October 16 at 8:14 AM logoIntrexon Crop Protection Achieves Milestone in Development of Pioneering Self-Limiting Fall Armyworm Solution - October 16 at 8:14 AM logoGlobal Zika Virus Vaccines Industry Forecasts (2017-2021) by Market Size (Volume and Value), Sales Price, &Gross Margin - October 13 at 10:30 AM logoIntrexon Lower For Fourth Day In A Row - October 13 at 10:30 AM logoZIOPHARM Announces Three Presentations at the 2017 Annual Meeting of the Society for Neuro-Oncology - GlobeNewswire (press release) - October 12 at 10:29 AM logoIntrexon Corporation (XON) Given Average Rating of "Hold" by Brokerages - October 11 at 6:36 PM logoOxitec do Brasil Receives Prestigious Award for Innovation and Impact - October 11 at 9:46 AM logoOncoSec Initiates Registration Directed Clinical Trial, KEYNOTE-695, Of ImmunoPulse® IL-12 In Combination With Merck's KEYTRUDA® (pembrolizumab) - October 10 at 8:33 AM logoIntrexon Corporation (XON): How Does It Impact Your Portfolio? - October 6 at 8:30 PM logoIntrexon Corporation (XON) Stock Rating Reaffirmed by Northland Securities - October 6 at 7:18 PM logoAnalysts Are Expecting Gas Fermentation to Be Huge for Intrexon. Here's Why They're Wrong. - October 6 at 3:29 PM logoETFs with exposure to Intrexon Corp. : October 6, 2017 - October 6 at 3:29 PM logoGriffin Securities Reiterates Buy Rating for Intrexon Corporation (XON) - October 6 at 9:36 AM logo Brokerages Anticipate Intrexon Corporation (XON) Will Announce Quarterly Sales of $55.17 Million - October 6 at 8:58 AM logoIntrexon Corporation's (XON) Outperform Rating Reiterated at JMP Securities - October 5 at 2:56 PM logoIntrexon Corp. breached its 50 day moving average in a Bullish Manner : XON-US : October 5, 2017 - October 5 at 1:41 PM logoTransfer of Regulatory Jurisdiction for Oxitec's Self-limiting Friendly™ Aedes in the United States - October 4 at 2:16 PM logo Brokerages Anticipate Intrexon Corporation (XON) Will Post Earnings of -$0.22 Per Share - October 4 at 9:10 AM logoOxitec to Build State-of-the-Art Mosquito Egg Production Unit - September 20 at 11:18 AM logoAll You Need To Know About Intrexon Corporation’s (XON) Financial Health - September 20 at 11:18 AM logoIntrexon Corporation (XON) versus Ironwood Pharmaceuticals (IRWD) Head to Head Contrast - September 20 at 12:18 AM logoZIOPHARM Oncology Announces Updated Findings from Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent ... - GlobeNewswire (press release) - September 18 at 8:14 AM logoZIOPHARM Oncology Announces Updated Findings from Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma Presented at American Academy of Neurological Surgery Annual Meeting - September 18 at 8:14 AM logo$55.17 Million in Sales Expected for Intrexon Corporation (XON) This Quarter - September 17 at 3:54 AM logoIntrexon Corporation (XON) Receives Consensus Rating of "Hold" from Brokerages - September 16 at 7:14 PM logo Analysts Anticipate Intrexon Corporation (XON) to Announce -$0.22 Earnings Per Share - September 15 at 4:24 PM logoETFs with exposure to Intrexon Corp. : September 14, 2017 - September 15 at 11:45 AM logoIs Intrexon Corporation Stock Now a Bargain? - Motley Fool - September 13 at 4:29 PM logoIntrexon Corp. :XON-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017 - September 13 at 4:29 PM logoIs Intrexon Corporation Stock Now a Bargain? - September 13 at 11:38 AM logoIntrexon Corporation (XON) Presents At Baird's 2017 Global Healthcare Conference - Slideshow - September 8 at 10:48 AM logoPfizer's Acute Leukemia Drug Mylotarg Approved by the FDA - September 5 at 8:35 PM logoIntrexon (XON) Oxitec's Begins Field Trials of Genetically Engineered Diamondback Moth - September 5 at 8:35 PM logoOxitec's Innovative Solution to Tackle Growing Diamondback Moth Pest Issue Begins Field Trials - September 5 at 8:35 PM logoIntrexon (XON) Oxitec's Begins Field Trials of Genetically Engineered Diamondback Moth - - September 5 at 3:28 PM logoPfizer's Acute Leukemia Drug Mylotarg Approved by the FDA - Nasdaq - September 4 at 3:36 PM logoIntrexon to Participate in Upcoming Investor Conferences - September 1 at 4:01 PM logoOragenics Doses First Patient in Phase 2 Clinical Trial of AG013 for Oral Mucositis - Business Wire (press release) - August 31 at 11:29 AM logo Analysts Expect Intrexon Corporation (XON) Will Post Quarterly Sales of $55.17 Million - August 30 at 5:50 PM logoHead to Head Comparison: Galapagos NV (GLPG) & Intrexon Corporation (XON) - August 29 at 10:42 AM logoKrystal Biotech Wants To Raise $35 Million In IPO - August 25 at 12:53 PM logoInsider Buying: Intrexon Corporation (XON) Director Acquires 2,850 Shares of Stock - August 23 at 8:28 PM logoIntrexon Corporation (XON) Short Interest Update - August 22 at 11:10 PM logoIntrexon Corporation (XON) Given Average Rating of "Hold" by Analysts - August 22 at 6:50 PM logoIntrexon Corporation to Post Q3 2017 Earnings of ($0.23) Per Share, Griffin Securities Forecasts (XON) - August 17 at 7:52 AM logoIntrexon Corporation (XON) Forecasted to Post Q1 2018 Earnings of ($0.21) Per Share - August 16 at 11:44 AM



Intrexon Corporation (XON) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.